Device aided therapies are emerging as mainstay of treatment of Parkinson’s in the advanced stages of the condition and also in the "earlier" stages of advanced PD. With the numbers of patients set to double by 2040, the societal and medical costs of advanced PD are likely to be of enormous consequence to patients, carers, medical communities and also policymakers. Device based therapies therefore, chosen properly and in right patients have much to offer for patients, carers and health care professionals and can range from subcutaneous options ( such as the newly available levodopa or apomorphine) to deep brain stimulation and also experimental delivery methods using neurotrophic factors. In this comprehensive state of the art book we discuss these latest options from a global set of key opinion leaders and also emerging specialists using a gender balanced modern and nuanced approach .